Elörehaladott stádiumú Hodgkin-kóros betegek kezelése CCNU, etoposide és prednimustine (CEP) terápiával.

Translated title of the contribution: Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)

A. Illés, A. Bányai, G. Szegedi

Research output: Contribution to journalReview article

Abstract

The authors treated 21 advanced, pretreated Hodgkin's disease patients with CEP (CCNU, etoposide, prednimustine) polychemotherapy between March 1988 and February 1993. Complete remission was achieved in 4 patients, partial remission in 8 patients, while 9 patients were unresponsive to treatment. None of the complete responders relapsed during the follow-up period, and the median duration of remission was 24 months. The median survival for the unresponsive and partially responsive patients was less than half a year. Side-effects included gastrointestinal symptoms, myelosuppression and alopecia, but treatment-related deaths did not occur. The present data confirm the favourable impact of CEP polychemotherapy on pretreated, advanced Hodgkin's disease patients.

Original languageHungarian
Pages (from-to)1187-1190
Number of pages4
JournalOrvosi hetilap
Volume135
Issue number22
Publication statusPublished - May 29 1994

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this